These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28928939)

  • 1. Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity.
    Gilberg E; Stumpfe D; Bajorath J
    F1000Res; 2017; 6():. PubMed ID: 28928939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Series of screening compounds with high hit rates for the exploration of multi-target activities and assay interference.
    Stumpfe D; Gilberg E; Bajorath J
    Future Sci OA; 2018 Mar; 4(3):FSO279. PubMed ID: 29568568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target Annotations.
    Hu Y; Jasial S; Gilberg E; Bajorath J
    AAPS J; 2017 May; 19(3):856-864. PubMed ID: 28265982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds.
    Jasial S; Hu Y; Bajorath J
    J Med Chem; 2017 May; 60(9):3879-3886. PubMed ID: 28421750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring structure-promiscuity relationships using dual-site promiscuity cliffs and corresponding single-site analogs.
    Hu H; Bajorath J
    Bioorg Med Chem; 2020 Jan; 28(1):115238. PubMed ID: 31818631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.
    Hu Y; Bajorath J
    AAPS J; 2013 Jul; 15(3):808-15. PubMed ID: 23605807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing compound activity records and promiscuity degrees in light of publication statistics.
    Hu Y; Bajorath J
    F1000Res; 2016; 5():. PubMed ID: 27347396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent Cell-selective Analog Series as Constellation Luminaries in Chemical Space.
    Naveja JJ; Medina-Franco JL
    Mol Inform; 2020 Dec; 39(12):e2000061. PubMed ID: 32390313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.
    Zhao H
    Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays.
    Feldmann C; Yonchev D; Bajorath J
    Future Sci OA; 2021 Mar; 7(5):FSO685. PubMed ID: 34046190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of search parameters and criteria on compound selection, promiscuity, and pan assay interference characteristics.
    Hu Y; Bajorath J
    J Chem Inf Model; 2014 Nov; 54(11):3056-66. PubMed ID: 25329977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity artifacts in drug discovery and different facets of compound promiscuity.
    Bajorath J
    F1000Res; 2014; 3():233. PubMed ID: 25339989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rules for identifying potentially reactive or promiscuous compounds.
    Bruns RF; Watson IA
    J Med Chem; 2012 Nov; 55(22):9763-72. PubMed ID: 23061697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent hit series hidden in high-throughput screening data.
    Varin T; Didiot MC; Parker CN; Schuffenhauer A
    J Med Chem; 2012 Feb; 55(3):1161-70. PubMed ID: 22185196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistics and decision making in high-throughput screening.
    Coma I; Herranz J; Martin J
    Methods Mol Biol; 2009; 565():69-106. PubMed ID: 19551358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the primary screening efficiency by multiple replicate testing: a quantitative analysis of hit confirmation and false screening results of a biochemical assay.
    Zhang JH; Wu X; Sills MA
    J Biomol Screen; 2005 Oct; 10(7):695-704. PubMed ID: 16129776
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.